The company could secure up to $60.8m in proceeds, having previously raised equity and debt from investors such as Novartis, Sanofi and Elan Science One.
Proteostasis Therapeutics, a US-based cystic fibrosis treatment developer backed by several healthcare companies, set the range for its initial public offering on Nasdaq at $12 to $14 on Monday.
The company, which counts pharmaceutical firms Novartis and Sanofi, as well as healthcare company Perrigo, as shareholders, plans to issue 3.85 million shares, which would place the size of the IPO between $46.2m and $53.9m.
If the underwriters choose to fully exercise their right to purchase up to 577,500 additional shares,…
